Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

Trikafta wins Canadian approval for Trikafta in children with cystic fibrosis

By Brian Buntz | April 20, 2022

Vertex PharmaceuticalsVertex Pharmaceuticals Inc. (Nasdaq: VRTX) has won marketing authorization for the expanded use of Trikafta (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in children with cystic fibrosis who are between the ages of 6 and 11 years old.

The latest approval covers children with at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene.

The approval allows an additional dosage strength of Trikafta tablets consisting of elexacaftor 50 mg/tezacaftor 25 mg/ivacaftor 37.5 mg, and ivacaftor 75 mg.

According to the company, the new approval will provide a treatment option to roughly 500 children.

“This important milestone brings us one step closer to our ultimate goal of developing treatments for all patients living with CF,” said Dr. Reshma Kewalramani, chief executive officer and president at Vertex. “We will now work closely with all provinces and territories to secure access for eligible patients as quickly as possible.”

Before winning the new approval, Vertex conducted a 24-week Phase 3 open-label, multicenter study enrolling 66 children between 6 and 11.


Filed Under: Uncategorized

 

Tell Us What You Think! Cancel reply

You must be logged in to post a comment.

Related Articles Read More >

Amylyx
Amylyx notches first global approval for oral ALS therapy Albrioza
Novavax
FDA advisory panel backs Novavax COVID-19
Sage and Biogen
Zuranolone could offer rapid relief from postpartum depression 
Moderna
Moderna seeks FDA blessing for second COVID-19 vaccine booster

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50